Skip to content
Screener

West Pharmaceutical Services WST Contract Liabilities

Contract Liabilities at other companies

AptarGroup logo
AptarGroupATR
$47.84M+3.1%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$31.67M+278%
Dow logo
DowDOW
$1.64B+14.8%
Sonoco Products logo
Sonoco ProductsSON
$44.41M+4.5%
Trimas logo
TrimasTRS
$6.73M—
UFP Technologies logo
UFP TechnologiesUFPT
$4.8M+4.2%

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.7B+44.8%
Enterprise value$24.58B+45.8%
P/E43.7×+8.7×
P/S7.4×+1.7×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
Contract assets, December 31, 2025$$11.9
Contract assets, June 30, 202617.2
Change in contract assets - increase (decrease)$$5.3
Deferred income, December 31, 2025$$(53.7)
Deferred income, June 30, 2026(45.7)
Change in deferred income - decrease (increase)$$8.0

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's contract liabilities?
West Pharmaceutical Services (WST) reported contract liabilities of $45.7M in Q2 2026.
How has West Pharmaceutical Services's contract liabilities changed year-over-year?
West Pharmaceutical Services's contract liabilities decreased by 1.1% year-over-year, from $46.2M to $45.7M.
What is the long-term trend for West Pharmaceutical Services's contract liabilities?
Over 5 years (2020 to 2025), West Pharmaceutical Services's contract liabilities has grown at a -1.2% compound annual growth rate (CAGR), from $57.1M to $53.7M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.

Ask your AI about West Pharmaceutical Services's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude